FormalPara Key Points
Pharmaceutical-grade cannabidiol (CBD) represents the first in a new class of antiseizure medications
In randomized controlled trials, CBD reduced seizure frequency in patients with Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex
Open-label studies suggest the effectiveness of CBD treatment in patients with other epileptic conditions than those addressed by regulatory trials
The most common adverse events associated with CBD include somnolence, decreased appetite, diarrhea, and increased serum aminotransferases

Introduction

Epilepsy is one of the most common chronic disorders of the brain and affects approximately 70 million people worldwide [1, 2]. Most patients with epilepsy can reach sustained remission, while around one third continues to have seizures despite adequate treatment [3,4,5]. Although many new medications were approved in the last decades, the burden of drug-resistant epilepsy has remained stable over the years [6]. Treatment-resistant epilepsies have a great impact on cognitive and behavioral function and quality of life, and there is an urgent need to search for new therapeutic options [7].

Cannabis has been used to treat epilepsy since antiquity, and the interest in cannabis-based therapies has increased in the last decade. Cannabidiol (CBD), which is one major constituent of the Cannabis sativa plant, has anti-seizure properties and does not produce euphoric or intrusive side effects [8]. The lack of regulation and standardization in the medical cannabis industry, however, raises concerns about the composition and consistency of the products that are dispensed [9].

Recently, a plant-derived, highly purified CBD formulation with a known and constant composition has been approved by the US Food and Drug Administration (Epidiolex®) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) in patients aged ≥ 2 years and for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older. In the European Union, the drug (Epidyolex®) has been authorized by the European Medicines Agency for the treatment of seizures associated with DS and LGS, in conjunction with clobazam (CLB), in patients aged ≥ 2 years and is under regulatory review for the treatment of seizures in patients with TSC. This is the first in a new class of antiseizure medications and the only pharmaceutical formulation derived from the cannabis plant that has undergone review through the approval processes and received marketing authorization for these difficult-to-treat epileptic syndromes.

Clinical evidence about CBD treatment in patients with DS and LGS has been already reviewed [10,11,12]. Here, we summarize the currently available body of knowledge about the use of this Food and Drug Administration/European Medicines Agency-approved oral formulation of pharmaceutical-grade CBD in patients with other epileptic conditions and suggest implications for clinical practice and future research.

Methods

The results of this systematic review were reported according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

The relevant studies were identified through MEDLINE (accessed by PubMed as of October 2020, week 4) and the US National Institutes of Health Clinical Trials Registry (http://www.clinicaltrials.gov). Search strategies are outlined in the Electronic Supplementary Material (ESM). There were no date limitations or language restrictions. The protocol was not registered previously.

The following types of studies were included: clinical trials, cohorts, case-control, cross-sectional, clinical series, and case reports. Self-reported surveys, reviews, meta-analyses, editorials, commentaries, and expert opinions were excluded. Participants had to meet the following criteria: any sex, any ethnicity, any age, diagnosis of epilepsy, receiving plant-derived, highly purified (> 98% w/w) CBD in a sesame oil-based oral solution (Epidiolex/Epidyolex®) for the treatment of seizures. We excluded studies that recruited only patients with LGS or DS, non-epilepsy disorders (e.g., pain, sleep), or patients with non-epileptic seizure types (e.g., non-epileptic myoclonus such as Lance–Adams syndrome). The drug manufacturer was contacted for information about any unpublished or ongoing studies. Reference lists of the selected articles were reviewed to identify additional reports of relevant studies.

Two review authors independently assessed studies for inclusion and extracted the following information from included studies: main study author and age of publication, number and demographics of participants, seizure outcomes (e.g., seizure frequency, 50% responder rate, seizure-free rate, seizure severity), safety outcomes (e.g., adverse event rate, rates of individual adverse events), and other effectiveness and clinical outcomes (e.g., retention rate, cognitive function, behavior, mood, brain imaging). Any disagreement was resolved by discussion with a third review author.

Results

Five hundred and seventy records were identified by database and trial register searching. Fifty-seven studies were retrieved for detailed assessment, of which 42 were eventually included for the review (Fig. 1). The included studies were randomized placebo-controlled trials [13, 43, 47], open-label interventional studies and their subgroup analyses [14, 15, 17, 18, 20,21,22,23,24, 26,27,28,29,30, 32, 34,35,36,37,38, 41, 42, 48,49,50,51,52], retrospective chart reviews [39, 44, 46], clinical series [19, 40, 53], and case reports [16, 25, 31, 33, 45, 54]. The participants of the studies included patients of pediatric age [14,15,16,17, 19, 28, 30, 31, 40, 41, 45, 46, 50, 52, 53], adult age [25, 32, 33, 36, 47, 48, 51, 54], and both pediatric and adult age [13, 18, 20,21,22,23,24, 26, 27, 29, 34, 35, 37,38,39, 42,43,44, 49]. Details of the characteristics of participants and outcomes of the included studies are provided in the ESM.

Fig. 1
figure 1

Flow diagram of the study selection process. CBD cannabidiol

Across the trials, purified CBD was administered as adjunctive treatment at dosages up to 50 mg/kg/day. Most studies aimed to assess the efficacy and safety of CBD treatment, and study endpoints included seizure frequency reduction, seizure response rate, seizure freedom, change in seizure severity, treatment discontinuation, and occurrence of adverse events. Eight studies were primarily aimed to describe pharmacokinetic analyses or drug–drug interactions between CBD and antiseizure or non-antiseizure medications [17, 23, 25, 33, 39, 43, 47, 54]. Seven studies included cognitive and/or quality-of-life measures [20,21,22, 32, 36, 50, 51], and three mainly focused on functional brain imaging assessment [35, 49, 51].

18 studies provided outcome data according to individual epileptic conditions or etiologies, including TSC, CDKL5 deficiency, Aicardi syndrome, Doose syndrome, Dup15q syndrome, epilepsy with myoclonic absences, Sturge–Weber syndrome, SYNGAP1 developmental and epileptic encephalopathy, epilepsy of infancy with migrating focal seizures, SCN8A-related epilepsy with encephalopathy, epileptic spasms, focal cortical dysplasia, cerebral dysgenesis, and lissencephaly; efficacy and tolerability data were also available for patients presenting with febrile infection-related epilepsy syndrome, and status epilepticus (Table 1). Twenty-four studies included patients with uncontrolled or treatment-resistant epilepsy of different etiologies, which were listed or not in the original papers, and outcomes were described for the whole cohorts without details for individual conditions (Table 2).

Table 1 Main clinical outcomes according to epilepsy condition or etiology
Table 2 Main clinical outcomes in patients with treatment-resistant epilepsy

Discussion

The existing data suggest that response to treatment with a highly purified, plant-derived CBD oil-based solution can be seen in patients across a broad range of epilepsy disorders and etiologies.

The highest-quality evidence is currently available for TSC. In one randomized, double-blind, controlled trial, CBD at both the dosages of 25 and 50 mg/kg/day produced a significantly greater percent reduction in TSC-associated focal and generalized seizure frequency and total seizure frequency, including focal sensory and epileptic spasms than placebo over the treatment period. The 50% responder rate among patients taking CBD was around 40% and substantially overlapped the rate observed in patients with TSC who were recruited in a prior expanded access study of CBD up-titrated to a maximum dose of 50 mg/kg/day within the frame of treatment-resistant epilepsies [20]. Further, the administration of purified CBD as adjunctive therapy at a dosage range of 10–50 mg/kg/day resulted in electrographic and clinical response in patients with TSC with refractory epileptic spasms enrolled in an open-label study: a reduction in epileptic spasm frequency was observed after 2 weeks of treatment, resolution of hypsarrhythmia correlated with the reduction in epileptic spasms, and all patients were free from epileptic spasms at 12 months [41]. Subjective improvements in cognitive and behavioral domains were also seen alongside improvement of background activity [41].

Open-label drug trials provide class III evidence for the efficacy of CBD administration in patients with CDKL5 deficiency disorder and Aicardi, Doose, and Dup15q syndromes, which are common causes of epileptic encephalopathies. Add-on treatment with pure CBD was associated with a significant reduction in baseline monthly seizure frequency at week 12, and no difference in seizure percent change was observed between week 12 and week 48, suggesting sustained efficacy. Long-term response to treatment was further reported over 2–4 years in patients with medically refractory epilepsy, including CDKL5 epileptic encephalopathy and epilepsy with myoclonic absences [30]. Remarkably, patients enrolled in these studies were among the most treatment-resistant patients at each center and had syndromes characterized by a poor outcome, with a high incidence of status epilepticus, use of rescue medication, and sudden unexpected death in epilepsy. They had high baseline seizure frequency and a number of concomitant antiseizure medications, and many had never obtained seizure control despite pharmacological and non-pharmacological interventions, including vagus nervus stimulation, dietary changes, and surgical treatments. In this scenario, the rates of seizure response and even seizure freedom for a few cases are suggestive of clinically relevant CBD efficacy.

A significant decrease in seizure frequency from 80 to 95% has been observed with CBD add-on therapy in patients with SYNGAP1 developmental and epileptic encephalopathy, accompanied by an improvement of background electroencephalogram activity and interictal anomalies. The reduction in drop attacks and myoclonic seizures, which are associated with a high risk of seizure-related injuries [55], could determine a favorable effect on the general condition of the patients. Interestingly, syngap1 heterozygous mutations induce an increase in the transient receptor potential cation channel subfamily V member 1 protein, which can be one of the mechanisms underlying the excitatory/inhibitory imbalance in drug-resistant epilepsy related to SYNGAP1 mutations [56, 57], and CBD has been shown to induce a rapid activation and desensitization of the transient receptor potential cation channel subfamily V member 1 [58].

One randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of CBD titrated to a target dose of 40 mg/kg/day in patients with infantile spasms aged 1–24 months had its primary endpoint measure based on an electroencephalogram and was stopped as it met the prespecified “No-Go Criteria” in its pilot phase after the recruitment of nine participants; improvement in caregiver and physician global impression of change was observed in most cases [14]. Clinical improvement following add-on CBD treatment was, instead, clearly observed in children aged between 3 and 16 years who presented with refractory epileptic spasms and participated in one open-label study: around 70% of patients were responders at 2 weeks, one third were free from epileptic spasms after 2 months, and 60% had a resolution in their hypsarrhythmia pattern [41].

In the population of patients with medically refractory epilepsy, CBD given as an adjunct treatment at 5–50 mg/kg/day exhibited an appreciable reduction in seizure frequency in a subset of patients with Sturge–Weber syndrome, focal cortical dysplasia, lissencephaly, brain tumor-related epilepsy, and frontal and temporal lobe epilepsy of unknown etiology. Finally, in the setting of emergency and urgency, pharmaceutical-grade purified CBD proved beneficial in a series of children treated for highly refractory seizures attributed to febrile infection-related epilepsy syndrome and individual cases of refractory status epilepticus.

The overall tolerability profile of purified CBD was favorable across the different epileptic conditions and substantially overlapped that reported in patients with DS and LGS enrolled in randomized controlled trials [10, 11]. The most common adverse events observed during treatment included somnolence, gastrointestinal symptoms, decreased appetite, and weight loss.

The incidence of somnolence was generally higher in patients concomitantly taking CLB. The increased serum level of N-desmethyl-clobazam, the active metabolite of CLB, via inhibition of cytochrome P450 2C19 by CBD is likely to contribute to the risk [59]. Slow titration of CBD and dose adjustment of CLB can alleviate the side effect when the two drugs are concomitantly administered [52]. Further, as it is not easy to distinguish benzodiazepine toxicity from CBD-related adverse events on a clinical basis, therapeutic drug monitoring may be recommended before CBD administration and after any dose increase [60].

Gastrointestinal symptoms were generally mild to moderate in severity and usually evident within the first months of treatment. The sesame oil-based drug vehicle and the effects of CBD on the gut microbiome may contribute to diarrhea [61]. The lack of appetite and decreased weight are thought to be directly related to CBD as they occurred also independently from diarrhea [30]. Clinically significant weight loss emerged typically only after about 6 months of treatment.

The currently available data indicate no adverse effects involving cognitive or adaptive functioning related to treatment with purified CBD [36, 50]. Improvement in cognition, behavior, mood, and multiple domains of health-related quality of life has been reported during CBD treatment in patients with TSC [20], children and young adults with severe childhood-onset epilepsy [22], and adult patients with refractory epilepsy [32]. These effects were independent of the reduction in seizure burden and may result from the changes induced by CBD in the connectivity related to executive functioning and emotional and attentional control processes, as observed in functional imaging studies [35, 49, 51]. Further, the lack of any impact on brain morphometry in terms of gray matter volume and cortical thickness changes despite positive action at molecular targets supports the safety of CBD in patients with treatment-resistant epilepsy, at least in the short and intermediate term [42].

Elevation of liver function tests occurred during CBD treatment. Most of the patients who experienced a rise in serum transaminases were concomitantly taking valproic acid (VPA). As CBD does not affect systemic concentrations of VPA or its metabolite, 4-ene-VPA [43], the interaction between CBD and VPA is most likely pharmacodynamic rather than pharmacokinetic. The interaction observed at the level of in vitro hepatic mitochondria could be the mechanism at the basis of the clinical findings [62, 63]. Interestingly, several patients who presented with elevations of liver function tests during the expanded access program were re‐titrated to baseline CBD dose after the withdrawal of VPA and did not experience any further laboratory abnormalities [23, 26]. Given the risk of hepatocellular injury, slow up-titration and close monitoring of liver enzymes are recommended, mostly during the initial phases of treatment, in patients taking VPA, following changes in the CBD dose and the addition of or changes in medications with known effect on the liver, such as VPA and CLB [64].

A drug–drug interaction that can have clinical relevance is that between CBD and the mechanistic target of rapamycin inhibitors, which are used as treatment options for TSC-associated manifestations, including subependymal giant cell astrocytomas, renal angiomyolipomas, and focal seizures. Cannabidiol can result in increased serum concentrations of sirolimus (or rapamycin) and everolimus, likely via inhibition of cytochrome P450 3A4 [39]. Close monitoring of mechanistic target of rapamycin inhibitor serum concentrations, safety laboratory studies, and occurrence of adverse events is warranted, and a dose reduction may be required. The increase in mechanistic target of rapamycin inhibitor levels can be particularly significant in patients concomitantly treated with the ketogenic diet, as both treatments are associated with similar metabolic derangements [65].

While there was no treatment-related thrombocytopenia during the phase III trials, a single-center systematic chart review reported this adverse event in 10% of the pediatric (aged < 21 years) patients diagnosed with LGS, DS, or other treatment-resistant epilepsies who were prescribed pharmaceutical-grade CBD [46]. Although all patients were concurrently treated with CBD and VPA, thrombocytopenia occurred independently of VPA doses and concentrations, and it was usually reversible with adjustments in the dosage of CBD or VPA; one case recovered spontaneously. If this finding is confirmed, monitoring for thrombocytopenia when adding CBD to a regimen that includes VPA may be also warranted.

The characteristics of the studies comprised in this review need to be considered in the interpretation of the findings. Major limitations included the open-label and uncontrolled design of the majority of the studies. The lack of blinding and comparator groups increases the potential for bias owing to the variable natural history of seizures and the high expectations for treatment [66]. The issue of the placebo response can be especially relevant in paediatric studies of CBD treatment because of the intense media and family interest in the compound [67]. The expectation of efficacy effect, however, is rarely sustained over time, and studies reporting long-term follow-up data can reduce or control it. Parent-reported measures of quality of life and cognitive and behavioral changes may be subjective views of the caregiver rather than patient experiences, and additional studies are needed to assess the quality of life of caregivers alone or patients themselves [67]. Further, the limited study sizes limited the generalizability of the results and the determination of statistical significance.

Conclusions

The approval of CBD represents a milestone in the history of medical use of cannabinoids to treat seizure disorders. Pharmaceutical-grade CBD oral solution is the first product made directly from the cannabis plant rather than created synthetically to be authorized by regulatory agencies, and the first in a new class of antiseizure medications. Experimental data demonstrated that CBD may have antiseizure properties in a broad range of epilepsy syndromes and etiologies [68, 69], and open-label studies suggested the effectiveness of purified CBD in the treatment of children and adults presenting with other epilepsy syndromes and seizure types than those addressed by regulatory trials, including CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes, SYNGAP1 encephalopathy, and Sturge–Weber syndrome. Of note, results cannot be directly transferred to other cannabis-derived products and non-purified forms of medical marijuana or its components.

Epileptic encephalopathies are associated with treatment-resistant seizures, high medication burden, neurodevelopmental delays, and disabling comorbidities [70]. To date, there are no drugs specifically approved for these conditions, and existing therapies can determine or exacerbate cognitive, behavioral, and motor disorders [27]. The currently available evidence about pharmaceutical-grade CBD provides preliminary support for additional research. It is, however, worth noticing that clinical studies in orphan diseases necessarily vary from trials in non-rare conditions and are less likely to use randomization, blinding, and active comparators [71]. Considering the high morbidity and mortality associated with uncontrolled epilepsy and the challenge to generate significant statistical power within the framework of traditional randomized, controlled trials, novel trial designs should be considered [72].